Balaxi Pharma's PAT up by 11% yoy in Q3FY22; stock jumps ~4.5%

15 Feb 2022 , 03:29 PM

Balaxi Pharmaceuticals Ltd. jumped 4.65% in today’s trade after its results announcement for the quarter and nine months ended December 2021. At around 3.27 PM, it was trading at Rs426.20 against its previous closing price of Rs407.35. It touched day’s high and low of Rs429.25 and Rs407.05 respectively in today’s trade.

Company reported a 11% growth in its PAT for Q3FY22 at Rs12.18 crore against Rs10.95 crore for Q3FY21. Whilst PAT for 9M ended December 2021 up by 17% at Rs34.95 crore against Rs29.74 crore for previous 9M period.

Company’s revenue for Q3FY22 recorded a decline of 6% yoy at Rs61.70 crore against Rs66 crore in the previous quarter. While revenue for the 9M period ended December 2021 gained 7% at Rs190.20 crore.

EBITDA for the quarter under review was reported at Rs13.20 crore as against Rs11.90 crore in the previous corresponding quarter, up by 11% yoy. EBITDA for the 9M period ended December 2021 was Rs39.90 crore as compared to Rs32.10 crore for Q3FY21, up by 24% yoy.

EBIDTA margin for Q3FY22 reported at 21% as against 18%, up by 330 bps. PAT margin gained 313 bps at 19.7% as compared to 16.6%.